Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
44 Results for "
thalassemia
" in MedChemExpress (MCE) Product Catalog:
Products (44)
44 Results for "thalassemia" in MCE Product Catalog:
50
50 Publications Verification
Cat. No.: HY-B0568
CAS No.: 30652-11-0
Target:
Research Areas:
Cardiovascular Disease Infection Neurological Disease Cancer
Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone can inhibit KDM. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study .
6
6 Cited Publications
Cat. No.: HY-112220
CAS No.: 2095668-10-1
Target:
Research Areas:
VIT-2763, an oral ferroportin inhibitor, inhibits hepcidin binding to ferroportin and blocks iron efflux. VIT-2763 has the potential in the treatment of β-thalassemia .
4
Research Areas:
Pyridoxal isonicotinoyl hydrazone is an orally active and lipophilic iron-specific chelator that acts as a non-competitive inhibitor of ferrochelatase (FECH) by binding iron ions. Pyridoxal isonicotinoyl hydrazone disrupts heme biosynthesis, leading to reduced FECH stability and increased protoporphyrin IX (PPIX) accumulation. Pyridoxal isonicotinoyl hydrazone is promising for research of iron-overload diseases (e.g., β-thalassemia) .
3
3 Cited Publications
Target:
Research Areas:
DMT1 blocker 1 is an orally active blocker of divalent metal transporter 1 (DMT1) with an IC50 of 0.64 μM. DMT1 blocker 1 inhibits intestinal cell absorption of non-heme iron, thereby alleviating iron overload by blocking the DMT1 transporter. DMT1 blocker 1 demonstrates significant efficacy in rodent models of acute iron hyperabsorption. DMT1 blocker 1 is useful for studying iron overload disorders such as hereditary hemochromatosis and thalassemia .
1
Target:
Research Areas:
Pociredir (FTX-6058) is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir can induce HbF protein expression in cell and murine models. Pociredir can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .
1
1 Cited Publications
Synonyms: FTX-6058 hydrochloride
Target:
Research Areas:
Pociredir (FTX-6058) hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir hydrochloride can induce HbF protein expression in cell and murine models. Pociredir hydrochloride can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .
Cat. No.: HY-P10272
CAS No.: 1628323-80-7
Synonyms: PTG-300
Target:
Research Areas:
Synonyms: CN328
Target:
Research Areas:
CN128 hydrochloride (CN328) is an orally active and selective iron chelator. CN128 is used for the research of β-thalassemia .
Synonyms: GT-56-252
Target:
Research Areas:
Deferitrin (GT-56-252), a desferrithiocin (DFT) analogue, is an orally active trident iron chelator. Deferitrin is used for chronic iron overload due to transfusional therapy. Deferitrin has the potential for beta-thalassemia major .
Target:
Neridronate is a bisphosphonate. Bisphosphonates initiate the Apoptotic process. Neridronate sodium reduces the levels of bone resorption, bone turnover markers, the degree of back pain, and the risk of fractures. Neridronate inhibits capillary tube formation. Neridronate itself has weak anticancer activity, but liposomal encapsulation enhances this activity. Neridronate can be used in research related to demineralizing metabolic bone diseases, thalassemia-associated osteoporosis, chronic inflammatory diseases, cancer, and osteogenesis imperfecta .
Cat. No.: HY-169761B
Research Areas:
(R,R)-dWIZ-1 TFA is the (R,R) enantiomer of dWIZ-1 (HY-159098). dWIZ-1 is a potent WIZ molecular glue degrader. (R,R)-dWIZ-1 TFA can be used in studies related to sickle cell disease and β-thalassemia .
Cat. No.: HY-P99720A
CAS No.: 1373715-00-4
Synonyms: RAP-536
Target:
Research Areas:
Cat. No.: HY-B0568R
CAS No.: 30652-11-0
Target:
Deferiprone (Standard) is the analytical standard of Deferiprone. This product is intended for research and analytical applications. Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study .
Cat. No.: HY-178486
CAS No.: 2619408-35-2
Research Areas:
SH6 is a CRBN-dependent proteasome degrader that targets ZBTB7A. SH6 can be used in the research of sickle cell disease and β-thalassemia .
Cat. No.: HY-16912
CAS No.: 911714-45-9
Synonyms: SP-420
Target:
Research Areas:
Petadeferitrin (SP-420) is a tridentate iron chelator belonging to the class of iron chelators, with orally activity. Petadeferitrin can be used in research related to β-thalassemia .
Cat. No.: HY-W015881
CAS No.: 595-37-9
Synonyms: NSC-16045; NSC-741804
Target:
Research Areas:
Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid can be used in the study of β-thalassemia and sickle cell disease .
Cat. No.: HY-147278
CAS No.: 2646704-10-9
Synonyms: Divesiran; SLN124
Research Areas:
Manusiran (Divesiran) is a GalNac-siRNA targeting liver and transmembrane serine protease 6 (Serine protease 6). Manusiran increases hepatic Hepcidin synthesis and plasma levels by silencing TMPRSS6, a negative regulator of hepcidin production, and limits the availability of iron required for erythropoiesis. Combined use of Manusiran with Deferiprone (HY-B0568) reduces ineffective erythropoiesis and hepatic iron overload in a mouse model of β-thalassemia. Manusiran can be used for research on polycythemia vera, type 1 hereditary hemochromatosis, and β-thalassemia .
Cat. No.: HY-130136A
Target:
Research Areas:
TMPRSS6-IN-1 (TFA) is a potent inhibitor of TMPRSS6 (Matriptase-2), belonging to TTSPs (transmembrane serine protease). TMPRSS6, is a type II TTSP, the genetic reduction of which will improve symptoms of hemochromatosis and beta thalassemia in mice .
Cat. No.: HY-W767164
Target:
Research Areas:
Deferiprone O-β-D-glucuronide sodium is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide sodium can be used to investigate its ability to reduce iron burden in patients with β-thalassemia .
Cat. No.: HY-130136
CAS No.: 2088415-78-3
Target:
Research Areas:
TMPRSS6-IN-1 (compound 8) is a potent inhibitor of TMPRSS6 (Matriptase-2), belonging to TTSPs (transmembrane serine protease). TMPRSS6, is a type II TTSP, the genetic reduction of which will improve symptoms of hemochromatosis and beta thalassemia in mice .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
